A retrospective study of Crizotinib as a 1st and 2nd line therapy in ALK-positive lung cancer in an Indian Population

Trial Profile

A retrospective study of Crizotinib as a 1st and 2nd line therapy in ALK-positive lung cancer in an Indian Population

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jul 2017 New trial record
    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top